טוען...

Multimorbidity, polypharmacy, and COVID-19 infection within the UK Biobank cohort

BACKGROUND: It is now well recognised that the risk of severe COVID-19 increases with some long-term conditions (LTCs). However, prior research primarily focuses on individual LTCs and there is a lack of data on the influence of multimorbidity (≥2 LTCs) on the risk of COVID-19. Given the high preval...

תיאור מלא

שמור ב:

מידע ביבליוגרפי
הוצא לאור ב:	PLoS One
Main Authors:	McQueenie, Ross, Foster, Hamish M. E., Jani, Bhautesh D., Katikireddi, Srinivasa Vittal, Sattar, Naveed, Pell, Jill P., Ho, Frederick K., Niedzwiedz, Claire L., Hastie, Claire E., Anderson, Jana, Mark, Patrick B., Sullivan, Michael, O’Donnell, Catherine A., Mair, Frances S., Nicholl, Barbara I.
פורמט:	Artigo
שפה:	Inglês
יצא לאור:	Public Library of Science 2020
נושאים:	Research Article
גישה מקוונת:	https://ncbi.nlm.nih.gov/pmc/articles/PMC7440632/ https://ncbi.nlm.nih.gov/pubmed/32817712 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0238091
תגים:	הוספת תג אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

Multimorbidity, polypharmacy, and COVID-19 infection within the UK Biobank cohort

פריטים דומים